Tag: American Society of Hematology
ASH 2020: Preclinical Models Identify CD74 as Potential Target for the...
Presentations during the virtual 62nd American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1 dose-escalation clinical trial with STRO-001, a CD74-targeted...
ASH 2020: Potential of Belantamab Mafodotin in Combination Standard Therapies in...
Multiple myeloma is the second most common hematological malignancy in the United States and is generally considered treatable, but not curable. Multiple myeloma...
What to Expect at ASH 2019: Seattle Genetics
With the 61st annual meeting of the American Society of Hematology about to begin, here are some of the presentations to look for.
This year...
Interim Phase I Data from Camidanlumab Tesirine (ADCT-301) Shows Encouraging Preliminary...
Clinical data from two ongoing Phase I clinical trials evaluating camidanlumab tesirine, also known as ADCT-301* or "Cami-T", in important subtypes of lymphoma and...
TRPH-222, a Novel Anti-CD22 ADC, has Significant Anti-Tumor Activity in NHL
A preclinical abstract describing TRPH-222, also known as CAT-02-106, an anti-CD22 antibody-drug conjugate or ADC being developed by Triphase Accelerator for the treatment of...
Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...
This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...
Pfizer Resubmits Application for Gemtuzumab Ozogamicin to European and American Regulators
In late January 2017 Pfizer's Biologics License Application (BLA) for gemtuzumab ozogamicin (Mylotarg®; previously known as CMA-676) was accepted for filing by the U.S....
Clinical Hold on Several Phase I Trials of Vadastuximab Talirine; Enrollment...
Earlier today Seattle Genetics, an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer, confirmed that it has...
Combination of Brentuximab Vedotin + Nivolumab Shows 90% Objective Response Rate...
The first reported data from an ongoing phase I/II clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics) in combination with nivolumab (Opdivo; Bristol-Myers Squibb...
Antibody-drug Conjugate Targeting CD74 Exhibits Potent Anti-tumor Activity in Multiple Malignant...
Sutro Biopharma, a biotechnology company developing best-in-class antibody drug conjugate (ADC) and multi-specific antibody-based therapeutics for cancer therapy, including immune-oncology therapies has launched IND-enabling studies, including...
